title: Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response.
abstract: BACKGROUND
  Platinum-based chemotherapy is the main treatment method for lung cancer patients. The genetic polymorphisms of Wnt-inducible signaling pathway protein 1 (WISP1) were reported to be associated with the development of diverse lung diseases. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response in Chinese lung cancer patients.
  
  
  METHODS
  A total of 556 lung cancer patients and 254 healthy controls were enrolled onto this study. The 28 polymorphisms of the WISP1 gene were genotyped by the Sequenom MassARRAY system.
  
  
  RESULTS
  We found that WISP1 rs16893344, rs2977530, rs2977537, and rs62514004 (P = .009, .033, .049, and .036, respectively) polymorphisms were related to susceptibility of lung cancer; and WISP1 rs11778573 (P = .023, nonsmokers), rs16893344 (P = .013, ≥ 50 years old), rs2977536 (P = .039, ≥ 50 years old; P = .044, nonsmokers; P = .047, non-small-cell lung cancer, respectively), rs2977549 (P = .013, smokers), and rs62514004 (P = .033, ≥ 50 years old) polymorphisms were significantly associated with platinum-based chemotherapy response in lung cancer patients.
  
  
  CONCLUSIONS
  Genotypes of WISP1 may be novel and useful biomarkers for diagnosis of lung cancer and evaluation of platinum-based chemotherapy response in lung cancer patients.
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Juan
authors: J
authors: Chen
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Ji-Ye
authors: JY
authors: Yin
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Xiang-Ping
authors: XP
authors: Li
authors: Affiliated Cancer Hospital of XiangYa School of Medicine, Central South University, Changsha, P.R. China.
authors: Ying
authors: Y
authors: Wang
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Yi
authors: Y
authors: Zheng
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Chen-Yue
authors: CY
authors: Qian
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Hui
authors: H
authors: He
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Chao
authors: C
authors: Fang
authors: Department of Oncology, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors: Zhan
authors: Z
authors: Wang
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Yu
authors: Y
authors: Zhang
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Ling
authors: L
authors: Xiao
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Sai-Ying
authors: SY
authors: Wang
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China.
authors: Wei
authors: W
authors: Zhang
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
authors: Hong-Hao
authors: HH
authors: Zhou
authors: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China. Electronic address: liuzhaoqian63@126.com.
authors: Zhao-Qian
authors: ZQ
authors: Liu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics; D055511:CCN Intercellular Signaling Proteins / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017671:Platinum Compounds / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D055511:CCN Intercellular Signaling Proteins; C116396:CCN4 protein, human; D017671:Platinum Compounds; D011518:Proto-Oncogene Proteins
keywords: Genetic polymorphism; Lung cancer; Platinum-based chemotherapy; Susceptibility; WISP1